- Home
- EDIT vs HRZN Comparison
EDIT vs HRZN Comparison
Compare EDIT & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- HRZN
- Stock Information
- Founded
- EDIT 2013
- HRZN 2008
- Country
- EDIT United States
- HRZN United States
- Employees
- EDIT N/A
- HRZN N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- HRZN Finance/Investors Services
- Sector
- EDIT Health Care
- HRZN Finance
- Exchange
- EDIT Nasdaq
- HRZN Nasdaq
- Market Cap
- EDIT 269.8M
- HRZN 264.2M
- IPO Year
- EDIT 2016
- HRZN 2010
- Fundamental
- Price
- EDIT $3.92
- HRZN $6.21
- Analyst Decision
- EDIT Buy
- HRZN Hold
- Analyst Count
- EDIT 11
- HRZN 4
- Target Price
- EDIT $4.56
- HRZN $7.81
- AVG Volume (30 Days)
- EDIT 2.7M
- HRZN 752.7K
- Earning Date
- EDIT 11-03-2025
- HRZN 10-28-2025
- Dividend Yield
- EDIT N/A
- HRZN 21.26%
- EPS Growth
- EDIT N/A
- HRZN N/A
- EPS
- EDIT N/A
- HRZN N/A
- Revenue
- EDIT $38,901,000.00
- HRZN $97,144,000.00
- Revenue This Year
- EDIT N/A
- HRZN N/A
- Revenue Next Year
- EDIT N/A
- HRZN $9.61
- P/E Ratio
- EDIT N/A
- HRZN N/A
- Revenue Growth
- EDIT N/A
- HRZN N/A
- 52 Week Low
- EDIT $0.91
- HRZN $5.97
- 52 Week High
- EDIT $4.05
- HRZN $10.69
- Technical
- Relative Strength Index (RSI)
- EDIT 73.38
- HRZN 32.08
- Support Level
- EDIT $3.01
- HRZN $5.97
- Resistance Level
- EDIT $3.58
- HRZN $6.75
- Average True Range (ATR)
- EDIT 0.30
- HRZN 0.18
- MACD
- EDIT 0.10
- HRZN -0.01
- Stochastic Oscillator
- EDIT 91.42
- HRZN 26.67
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.